Simone, oncology polymath and leader

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Joe Simone was oncology’s polymath. Skilled and adept in patient care, scientific and clinical discovery, administrative leadership, education as well as mentoring to a generation of oncologists through his writings.

00003893-005
Simone with a patient at St. Jude Children’s Research Hospital in 1970. Photo courtesy of St. Jude Children’s Research Hospital.

Over the years we worked together on many shared endeavors including the National Comprehensive Cancer Network, the Huntsman Cancer Institute, and many cancer policymaking organizations. He was forever creative, insightful and astute.

But Joe’s genuine affection and respect for his colleagues and friends spilled over into everything he did.

Joe and I ran for president of ASCO in the same year. With the organization heavily weighted toward medical oncologists rather than pediatricians, that more than anything else enabled me to win.

Shortly after the election I received a handwritten letter from Joe. It said, in essence, that although he had hoped he would win, he was very pleased to see me in that role and hoped that we would have many opportunities to work together in the future.

Thirty years later, I still have that letter. Joe made a lasting impact on oncology and as well as on so many of his colleagues.

He will remain forever in the lives of so many of us.


The author is the former president, chief executive officer, and chancellor,

Fox Chase Cancer Center


Joseph V. Simone’s book, “Simone’s Maxims,” is available for download through the Cancer History Project.

Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
Robert C. Young, MD
Former president, chief executive officer, and chancellor, Fox Chase Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login